Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 293

Similar articles for PubMed (Select 19084294)

1.

Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.

Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, Pisano C, Vesci L, Barbarino M, Zuco V, De Cesare M, Zunino F.

Eur J Med Chem. 2009 May;44(5):1900-12. doi: 10.1016/j.ejmech.2008.11.005. Epub 2008 Nov 19.

PMID:
19084294
2.

Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.

Suzuki T, Matsuura A, Kouketsu A, Hisakawa S, Nakagawa H, Miyata N.

Bioorg Med Chem. 2005 Jul 1;13(13):4332-42.

PMID:
15927839
3.

Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.

Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, Miyata N.

J Med Chem. 2005 Feb 24;48(4):1019-32.

PMID:
15715470
4.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.

Mol Cancer Ther. 2008 Apr;7(4):759-68. doi: 10.1158/1535-7163.MCT-07-2026.

5.

CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.

Cao ZA, Bass KE, Balasubramanian S, Liu L, Schultz B, Verner E, Dai Y, Molina RA, Davis JR, Misialek S, Sendzik M, Orr CJ, Leung L, Callan O, Young P, Dalrymple SA, Buggy JJ.

Mol Cancer Ther. 2006 Jul;5(7):1693-701.

6.

Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.

Anandan SK, Ward JS, Brokx RD, Denny T, Bray MR, Patel DV, Xiao XY.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5995-9. Epub 2007 Aug 19.

PMID:
17827005
8.

Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.

Suzuki T, Matsuura A, Kouketsu A, Nakagawa H, Miyata N.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):331-5.

PMID:
15603949
9.

Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition, and binding mode study of SAHA-based non-hydroxamates.

Suzuki T, Nagano Y, Matsuura A, Kohara A, Ninomiya S, Kohda K, Miyata N.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4321-6.

PMID:
14643318
10.

Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.

Shinji C, Maeda S, Imai K, Yoshida M, Hashimoto Y, Miyachi H.

Bioorg Med Chem. 2006 Nov 15;14(22):7625-51. Epub 2006 Jul 31.

PMID:
16877001
11.

Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).

Schäfer S, Saunders L, Eliseeva E, Velena A, Jung M, Schwienhorst A, Strasser A, Dickmanns A, Ficner R, Schlimme S, Sippl W, Verdin E, Jung M.

Bioorg Med Chem. 2008 Feb 15;16(4):2011-33. Epub 2007 Nov 4.

PMID:
18054239
12.

Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.

Kim DK, Lee JY, Kim JS, Ryu JH, Choi JY, Lee JW, Im GJ, Kim TK, Seo JW, Park HJ, Yoo J, Park JH, Kim TY, Bang YJ.

J Med Chem. 2003 Dec 18;46(26):5745-51.

PMID:
14667227
13.

Differential protein acetylation induced by novel histone deacetylase inhibitors.

Glaser KB, Li J, Pease LJ, Staver MJ, Marcotte PA, Guo J, Frey RR, Garland RB, Heyman HR, Wada CK, Vasudevan A, Michaelides MR, Davidsen SK, Curtin ML.

Biochem Biophys Res Commun. 2004 Dec 17;325(3):683-90.

PMID:
15541343
14.

Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.

Lee S, Shinji C, Ogura K, Shimizu M, Maeda S, Sato M, Yoshida M, Hashimoto Y, Miyachi H.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4895-900. Epub 2007 Jun 13.

PMID:
17588744
15.

Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.

Price S, Bordogna W, Bull RJ, Clark DE, Crackett PH, Dyke HJ, Gill M, Harris NV, Gorski J, Lloyd J, Lockey PM, Mullett J, Roach AG, Roussel F, White AB.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):370-5. Epub 2006 Oct 24.

PMID:
17095213
16.

2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.

Mahboobi S, Sellmer A, Höcher H, Garhammer C, Pongratz H, Maier T, Ciossek T, Beckers T.

J Med Chem. 2007 Sep 6;50(18):4405-18. Epub 2007 Aug 11.

PMID:
17691763
17.

Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.

Hanessian S, Auzzas L, Giannini G, Marzi M, Cabri W, Barbarino M, Vesci L, Pisano C.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. Epub 2007 Sep 8.

PMID:
17892933
18.
19.

New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.

Mai A, Valente S, Nebbioso A, Simeoni S, Ragno R, Massa S, Brosch G, De Bellis F, Manzo F, Altucci L.

Int J Biochem Cell Biol. 2009 Jan;41(1):235-47. doi: 10.1016/j.biocel.2008.09.002. Epub 2008 Sep 12.

PMID:
18834955
20.

Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.

Huang WJ, Chen CC, Chao SW, Lee SS, Hsu FL, Lu YL, Hung MF, Chang CI.

ChemMedChem. 2010 Apr 6;5(4):598-607. doi: 10.1002/cmdc.200900494.

PMID:
20209563
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk